Sentences with phrase «after transplantation with»

Not exact matches

Medicaid participation after liver transplantation was more common in Medicaid - expansion states (25 percent) compared with non-expansion states (19 percent).

Because of the risk of severe rejection after transplantation, experts traditionally believed that children with these antibodies should wait for a heart that won't activate an antibody response.

At 10 years after transplantation, the organs from donors with unacceptable / high risk provided each recipient with more than 7 additional years of survival on average.

Steatosis — when the liver becomes infiltrated with fat — occurs frequently after liver transplantation, but little is known about its actual prevalence in transplant recipients, which risk factors are involved, or what effects the condition has on patients» survival.

Even with immunosuppressive therapy, 10 to 15 percent of kidney recipients experience rejection during the first year after transplantation.

Transplant recipients with low urinary CXCL9 protein six months after transplantation were unlikely to experience rejection or loss of kidney function over the next 18 months.

However, Eggan and McCarroll emphasized that now that this phenomenon has been found, inexpensive gene - sequencing tests will allow researchers to identify and remove from the production line cell cultures with concerning mutations that might prove dangerous after transplantation.

«The studies clearly show that a high - fat diet with or without the genetic loss of ApoE can alter the immune response in mice after heart transplantation,» he continued.

If rejection occurred in those with mostly IgG4 antibodies, it was usually much later after transplantation.

Patients with mostly IgG3 donor - specific HLA antibodies had a higher likelihood of organ rejection soon after transplantation.

Pretreating mice with STAR2 protected them from developing GvHD after immune cell transplantation.

After analyzing information on 88,209 donors (176,418 kidneys), the researchers found that although the discarded kidneys in these pairs frequently had traits that are typically considered unappealing, the partner kidneys that shared many, if not all of the same traits performed well after being used for transplantation despite being used in older recipients with more medical probAfter analyzing information on 88,209 donors (176,418 kidneys), the researchers found that although the discarded kidneys in these pairs frequently had traits that are typically considered unappealing, the partner kidneys that shared many, if not all of the same traits performed well after being used for transplantation despite being used in older recipients with more medical probafter being used for transplantation despite being used in older recipients with more medical problems.

Pattern of employment and associated factors in long - term lymphoma survivors 10 years after high - dose chemotherapy with autologous stem cell transplantation.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Conditional survival and excess mortality after high - dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).

A Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidawith FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) ConsolidaWith or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

A Phase III Randomized Open - Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid - Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3)

Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Clostridium difficile Infection after Liver Transplantation

Horwitz et al 79 reported that donor MSC contributed to bone remodelling after allogeneic stem cell transplantation (SCT) in 3 children with osteogenesis imperfecta, a rare genetic disorder of type I collagen.

Hutter G and Thiel E Allogeneic transplantation of CCR5 - deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2.

Accelerated aging of immune system after hematopoietic stem cell transplantation Researchers demonstrated that hematopoietic stem cell transplantation in patients with hematological malignancies significantly accelerates aging of immune system.

Dr. Sucheston - Campbell will present a companion presentation based on this research, «Functional Genetic Variants on 14q32 Associate with Death Due to Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) within One Year after HLA - Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY - BMT Study),» on Saturday, Feb. 25, 6 p.m. at Gaylord Palms Convention Center, Florida Hall C. Dr. Hahn is senior author of that presentation.

Dr. Hahn will discuss this work in her presentation, «Novel genetic variants associated with death due to acute lymphoblastic leukemia within one year after HLA - matched unrelated donor blood and marrow transplantation (DISCOVeRY - BMT Study),» on Friday, February 24, 3:15 p.m. at Gaylord Palms Convention Center, Florida Hall E.

Researchers previously reported promising results in adolescents and young adults with XSCID who were treated with the St. Jude vector and low - dose chemotherapy after bone marrow transplantation failed to restore adequate immune protection.

By means of a non-obese diabetic / severe combined immunodeficiency disease (NOD / SCID) xenotransplant assay in combination with specific cell surface markers (CD44 + CD24 - / low), CSCs were enriched from metastatic and primary breast tumors and were shown to have the ability to reestablish tumor heterogeneity after transplantation [1].

At the University of Chicago Medicine, our transplant team works side - by - side with the patient, family and referring physician before, during and after transplantation to ensure the best possible outcome.

Spleen CD4 + T cells were harvested from mice 21 d after transplantation and cultured or not with VPA for 24 h. Western blot assay showed that VPA attenuated the phosphorylation level of Akt in a dose - dependent manner (Fig. 4F).

Administration of VPA to mice reconstituted with TCD - BM only caused no mortality, and pathological analysis showed no evidence of GVHD 60 d after transplantation (data not show).

The therapeutic potential of bone marrow transplantation (BMT) relies on the graft - versus - leukemia (GVL) effect, which is closely associated with graft - versus - host disease (GVHD), the major cause of morbidity and mortality after BMT (1 — 4).

We found that, in the allogeneic group, IFN - γ +, IL - 17A +, and IFN - γ / IL -17 A double - positive CD4 + T cells derived from spleen (Fig. 2A, 2B) and MLN (Supplemental Fig. 1A, 1B) increased since the early stage after transplantation compared with the syngeneic group, whereas the IFN - γ — and / or IL - 17A — producing CD8 + T cells increased only at the late stage (Supplemental Fig. 1C, 1D).

VPA (300 mg / kg / d) was injected i.p. into T cell recipients from day 0 after transplantation (n = 20), with vehicle treatment as control (n = 20).

We then treated BMT recipients with VPA or vehicle and recovered donor T cells from spleen and MLN of recipients on the indicated days after transplantation.

For example, we're one of a handful of hospitals in the country to offer total pancreatectomy with islet cell autotransplantation (autologous islet cell transplantation), a procedure aimed at preventing diabetes or reducing its effects after removal of the pancreas due to pancreatitis.

Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.

Interestingly, mice that had been treated with stem cells had more neurons four months after the transplantation than mice that had not been treated.

Worked directly with the Hospital Development and Community Outreach Manager to implement the strategic plan of training the new volunteers after the launch of the new on - line Wisconsin Donor Registry as well as training volunteers to speak publicly about donation / transplantation.